Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya (IPT)

This study has been completed.
Sponsor:
Collaborators:
Stichting Mondiale Tuberculose (SMT)
Kenya Medical Research Institute
Division of Leprosy Tuberculosis and Lung Disease, MOPHS, Kenya
Centres for Disease Control and Prevention, Kenya.
Central Reference TB laboratory, National Public Health Laboratory Service, MOPHS, Kenya
Kenya National AIDS & STI Control Programme
Information provided by (Responsible Party):
Eveline Klinkenberg, KNCV Tuberculosis Foundation
ClinicalTrials.gov Identifier:
NCT00850915
First received: February 24, 2009
Last updated: May 17, 2013
Last verified: May 2013
  Purpose

Isoniazid preventive therapy (IPT) is a well studied clinical intervention for primary and secondary prevention of active tuberculosis (TB) after infection with Mycobacterium tuberculosis. It is widely used in industrialized countries in TB outbreak management, focusing on high risk groups such as close contacts in the family, in congregate settings, and in the workplace amongst others. Individuals infected with Human Immunodeficiency Virus (HIV) have a markedly higher risk of acquiring a TB-infection and developing consequently active TB, making HIV-infected individuals a target population for IPT. Studies of IPT in HIV infected persons in the nineties demonstrated the efficacy of IPT in the prevention of active TB in Sub -Saharan Africa and more recent studies suggest that the protective effect remains present in individuals on antiretroviral therapy.

Despite the proven efficacy of IPT this intervention has not been taken up by most HIV and TB control programmes in Africa where the burden of TB/HIV is highest. The reasons for the low uptake of IPT are many and varied but include fears of expansion of isoniazid resistance and subsequently the development of multi -drug resistant TB with widespread use of IPT. Additionally screening protocols for excluding active TB and selecting persons for IPT have not been uniformly agreed upon. There have also been concerns that programmes designed to provide IPT may shift TB control programmes from their primary responsibility of finding and treating active TB. Finally it has been unclear as to which programme, between the HIV and the TB control programme, has the primary responsibility of managing the provision of the IPT intervention.

The World Health Organization and other technical agencies engaged in global TB control have recently re-emphasized the need to scale up IPT. In this proposal we outline an operational research study to evaluate the introduction of IPT at community level and to measure its effectiveness at preventing TB. The study is based on the context of expansion of Community-Based Direct Observed Therapy Short Course (CB-DOTS), home-based care and the concept of HIV prevention with positives (PwPs), where there is a real opportunity to focus on the household as a source of HIV-associated tuberculosis.

The study is designed as a cluster randomized trial. It compares the incidence of TB in household contacts including children under 5 of identified TB/HIV co-infected patients, who received IPT through proactive community intervention and those in a control group where the community was handled in the "usual way". In the intervention group household contacts of index cases of HIV positive, smear positive PTB will be visited at home and consenting contacts will be screened for active TB using a simple questionnaire. Those found to be fit will receive isoniazid 300mg (5 mg per Kg for children) once daily for 6 months, regardless of the HIV-status. Those found not to be fit will be referred for further evaluation at the nearest TB diagnostic centre. In the control group, routine care following national guidelines will be offered. This consists of contact invitation and assessment of eligibility for IPT, especially, in children less than 5 years. Both groups will be followed up monthly through household visits. Follow up will be for a total of 24 months including the six months when IPT is provided.

A confidential HIV screening test will be provided to all consenting contacts in both intervention and control group after appropriate counseling.

The primary outcome is the incidence of TB in the intervention and control household contacts. The difference in incidence between the two groups is a measure of efficacy of the intervention. In addition the efficacy of the intervention will be estimated stratified by HIV status of household contacts if data allows. Secondary outcomes are the incidence of adverse events, the incidence of TB-related symptoms, measures on the uptake of IPT (proportion of contacts starting and discontinuing IPT, treatment adherence) and programmatic indicators, i.e. percentage of persons eligible for IPT and resources needed.


Condition Intervention Phase
Tuberculosis
Other: community IPT
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Feasibility and Effectiveness of Community Based Isoniazid Preventive Therapy in Kenya

Resource links provided by NLM:


Further study details as provided by KNCV Tuberculosis Foundation:

Primary Outcome Measures:
  • incidence of TB in household contacts [ Time Frame: 12, 18, 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • incidence of adverse events in household contacts [ Time Frame: 12, 18, 24 months ] [ Designated as safety issue: Yes ]
  • incidence of TB-related symptoms in household contacts [ Time Frame: 12, 18, 24 months ] [ Designated as safety issue: No ]
  • proportion of household contacts starting IPT [ Time Frame: 12, 18, 24 months ] [ Designated as safety issue: No ]
  • proportion of household contacts discontinuing IPT [ Time Frame: 12, 18, 24 months ] [ Designated as safety issue: No ]
  • proportion of household contacts adhering to IPT treatment [ Time Frame: 12, 18, 24 months ] [ Designated as safety issue: No ]

Enrollment: 1259
Study Start Date: April 2009
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
in this arm contacts of enrolled TB-HIV index cases were actively approached and screened for TB and offered HIV testing by CHW at their homes
Other: community IPT

In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.

In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.

All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB.

2
no interventation was done in this group, they received the regulare care and follow up following NTP guidelines
Other: community IPT

In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.

In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.

All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB.


  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Index cases

  • New sputum smear positive pulmonary tuberculosis (PTB) patients initiating treatment for TB
  • HIV infected
  • Resident in the catchment area of the TB diagnostic facility
  • Written informed consent
  • Age equal or greater than 15 years.

Contacts

  • Household contacts of a HIV infected smear positive PTB
  • No plans to relocate to another area for at least the next two years
  • Asymptomatic (Fit) with no cough in last 2 weeks, fever, weight loss (or failure to gain weight in children), haemoptysis or chronic diarrhea at least for the last one month.
  • Written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00850915

Locations
Kenya
Makuyu H/C
Makuyu-Muranga, Central, Kenya
Kangemi HC
Nairobi, Nairobi North, Kenya
Huruma Lions -Central district
Nairobi, Nairobi North, Kenya
Blue House, Mathare
Nairobi, Nairobi South, Kenya
MMM, Mukuru, Embakasi
Nairobi, Nairobi South, Kenya
Soweto Kayole, Embakasi
Nairobi, Nairobi South, Kenya
Kibera AMREF
Nairobi, Nairobi South, Kenya
Remand H/C
Nairobi, Nairobi South, Kenya
Pumwani Majengo H/C
Nairobi, Nairobi South, Kenya
Jericho HC
Nairobi, Nairobi South, Kenya
KAPSABET District Hospital
Kapsabet-Nandi, North Rift, Kenya
NYALENDA
Kisumu district, Nyanza North, Kenya
Kadem leprosy, Migori
Migori District, Nyanza South, Kenya
Muhuru Health centre, Migori
Migori District, Nyanza South, Kenya
Awendo SDH
Rongo district, Nyanza South, Kenya
Nakuru West
Nakuru, RVS, Kenya
Lanet
Nakuru, RVS, Kenya
Narok District Hosp
Narok, RVS, Kenya
Sponsors and Collaborators
KNCV Tuberculosis Foundation
Stichting Mondiale Tuberculose (SMT)
Kenya Medical Research Institute
Division of Leprosy Tuberculosis and Lung Disease, MOPHS, Kenya
Centres for Disease Control and Prevention, Kenya.
Central Reference TB laboratory, National Public Health Laboratory Service, MOPHS, Kenya
Kenya National AIDS & STI Control Programme
Investigators
Principal Investigator: Jeremy M Chakaya, MD Centre for Respiratory Diseases Research, Kenya Medical Research Institute
Principal Investigator: Eveline Klinkenberg, PhD KNCV Tuberculosis Foundation, the Netherlands
  More Information

No publications provided

Responsible Party: Eveline Klinkenberg, senior epidemiologist, KNCV Tuberculosis Foundation
ClinicalTrials.gov Identifier: NCT00850915     History of Changes
Other Study ID Numbers: UR-01-2009-IPT-KENYA
Study First Received: February 24, 2009
Last Updated: May 17, 2013
Health Authority: Kenya: Kenya Medical Research Institute

Keywords provided by KNCV Tuberculosis Foundation:
tuberculosis
community IPT
isoniazid adverse events
tuberculosis incidence

Additional relevant MeSH terms:
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Isoniazid
Antitubercular Agents
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Fatty Acid Synthesis Inhibitors
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents

ClinicalTrials.gov processed this record on August 20, 2014